SK1172000A3 - Method and compositions for treating late phase allergic reactions and inflammatory diseases - Google Patents

Method and compositions for treating late phase allergic reactions and inflammatory diseases Download PDF

Info

Publication number
SK1172000A3
SK1172000A3 SK117-2000A SK1172000A SK1172000A3 SK 1172000 A3 SK1172000 A3 SK 1172000A3 SK 1172000 A SK1172000 A SK 1172000A SK 1172000 A3 SK1172000 A3 SK 1172000A3
Authority
SK
Slovakia
Prior art keywords
composition
ulmwh
antigen
allergic
reactions
Prior art date
Application number
SK117-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Tahir Ahmed
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of SK1172000A3 publication Critical patent/SK1172000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SK117-2000A 1997-08-04 1998-08-04 Method and compositions for treating late phase allergic reactions and inflammatory diseases SK1172000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/904,565 US5980865A (en) 1995-08-18 1997-08-04 Method for treating late phase allergic reactions and inflammatory diseases
PCT/US1998/016111 WO1999006025A1 (en) 1997-08-04 1998-08-04 Method and compositions for treating late phase allergic reactions and inflammatory diseases

Publications (1)

Publication Number Publication Date
SK1172000A3 true SK1172000A3 (en) 2001-03-12

Family

ID=25419368

Family Applications (1)

Application Number Title Priority Date Filing Date
SK117-2000A SK1172000A3 (en) 1997-08-04 1998-08-04 Method and compositions for treating late phase allergic reactions and inflammatory diseases

Country Status (25)

Country Link
US (2) US5980865A (enExample)
EP (1) EP1003479B1 (enExample)
JP (1) JP2001511439A (enExample)
KR (1) KR100551773B1 (enExample)
CN (1) CN1092049C (enExample)
AR (1) AR005221A1 (enExample)
AT (1) ATE323500T1 (enExample)
AU (1) AU8684698A (enExample)
BR (1) BR9811823A (enExample)
CA (1) CA2298445C (enExample)
DE (1) DE69834256T2 (enExample)
DK (1) DK1003479T3 (enExample)
ES (1) ES2260843T3 (enExample)
HU (1) HUP0003013A3 (enExample)
IL (1) IL134230A0 (enExample)
NO (1) NO20000558L (enExample)
NZ (1) NZ502498A (enExample)
PL (1) PL191796B1 (enExample)
PT (1) PT1003479E (enExample)
RU (1) RU2209624C2 (enExample)
SK (1) SK1172000A3 (enExample)
TW (1) TW585771B (enExample)
UA (1) UA75022C2 (enExample)
WO (1) WO1999006025A1 (enExample)
ZA (1) ZA986890B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use
CA2410577A1 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury
EP1511466B2 (en) 2002-02-18 2015-02-25 Ockham Biotech Limited Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2003090763A1 (en) * 2002-04-24 2003-11-06 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
JPWO2004084918A1 (ja) * 2003-03-25 2006-06-29 積水化学工業株式会社 皮膚止痒外用組成物
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
RU2240801C1 (ru) * 2003-10-02 2004-11-27 Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра СО РАМН Средство, обладающее противоаллергическим действием
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
RU2322987C2 (ru) * 2006-05-23 2008-04-27 Ольга Александровна Субботина Средство для лечения иммунных заболеваний кожи
CN101095693B (zh) * 2006-06-29 2010-10-13 重庆华邦制药股份有限公司 治疗皮炎的复方药物
PT2164501E (pt) * 2007-05-31 2016-06-02 Paradigm Biopharmaceuticals Ltd Xilanos sulfatados para tratamento ou profilaxia de doenças respiratórias
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
MX2013004575A (es) * 2010-10-29 2013-05-17 Opko Health Inc Disacaridos hipersulfatados para tratar trastornos relacionados con la elastasa.
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
US20120322759A1 (en) * 2011-05-12 2012-12-20 Aventis Pharma Sa Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3191091B1 (en) 2014-09-12 2020-08-26 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
TW201815394A (zh) 2016-08-16 2018-05-01 美商歐科製藥有限公司 具有改良口服生物可利用性之純七硫酸化雙醣
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
US20220211746A1 (en) * 2021-01-07 2022-07-07 Bionovax Corp. Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
ATE217796T1 (de) * 1991-05-02 2002-06-15 Yeda Res & Dev Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
CA2156735A1 (en) * 1993-02-22 1994-09-01 Ulrich-Christoph Von Arnim Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases
FR2704861B1 (fr) * 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9303612D0 (sv) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
IL134230A0 (en) 2001-04-30
RU2209624C2 (ru) 2003-08-10
DK1003479T3 (da) 2006-07-31
PL191796B1 (pl) 2006-07-31
NZ502498A (en) 2002-05-31
WO1999006025A1 (en) 1999-02-11
CN1269715A (zh) 2000-10-11
TW585771B (en) 2004-05-01
DE69834256T2 (de) 2007-02-01
ZA986890B (en) 1999-01-28
US5980865A (en) 1999-11-09
PL338551A1 (en) 2000-11-06
JP2001511439A (ja) 2001-08-14
US6193957B1 (en) 2001-02-27
CA2298445A1 (en) 1999-02-11
EP1003479A4 (en) 2001-01-17
KR100551773B1 (ko) 2006-02-13
BR9811823A (pt) 2000-08-15
CN1092049C (zh) 2002-10-09
NO20000558L (no) 2000-03-14
NO20000558D0 (no) 2000-02-03
EP1003479B1 (en) 2006-04-19
EP1003479A1 (en) 2000-05-31
HUP0003013A2 (hu) 2001-01-29
HUP0003013A3 (en) 2001-11-28
ATE323500T1 (de) 2006-05-15
CA2298445C (en) 2007-07-17
UA75022C2 (en) 2006-03-15
KR20010022533A (ko) 2001-03-15
AR005221A1 (es) 1999-04-28
ES2260843T3 (es) 2006-11-01
AU8684698A (en) 1999-02-22
HK1030370A1 (en) 2001-05-04
PT1003479E (pt) 2006-08-31
DE69834256D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
SK1172000A3 (en) Method and compositions for treating late phase allergic reactions and inflammatory diseases
JP3263723B2 (ja) 喘息を治療するための組成物、及び喘息にかかった患者を治療するための気管支内薬物の製造における超低分子量ヘパリンの使用
JP4585121B2 (ja) 薬剤療法に対する寛容を予防するための方法と組成物
WO1993019734A1 (en) Method and composition for treating antigen-induced and exercise-induced asthma
AU775161B2 (en) Method and compositions for treating late phase allergic reactions and inflammatory diseases
RU2179445C2 (ru) Способ и композиция для лечения астмы
MXPA00000992A (en) Method and compositions for treating late phase allergic reactions and inflammatory diseases
MXPA98001165A (en) Method and composition for the treatment of the
CZ2000426A3 (cs) Farmaceutický přípravek k léčení pozdní fáze alergické reakce a zánětlivé nemoci
HK1007060B (en) Ulmwh (ultra-low-molecular weight heparin) for treating asthma